{
  "trial_id": "NCT03529955",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Must understand the risks and the benefits/purpose of the study and provide signed and dated informed consent.",
      "label": "met"
    },
    {
      "criterion": "Must be 18 years at time of signing the informed consent form.",
      "label": "met"
    },
    {
      "criterion": "Willing to participate in all required evaluations and procedures in the study including the ability to swallow pills without difficulty.",
      "label": "unknown"
    },
    {
      "criterion": "Patients must have a diagnosis of DM based upon the characteristic cutaneous findings proposed by Sontheimer[6] and/or a skin biopsy consistent with DM.",
      "label": "met"
    },
    {
      "criterion": "Patients must be candidate for systemic therapy for their DM skin disease defined by inadequate response to aggressive sun protection along with the use of potent topical corticosteroids and/or immunomodulators.",
      "label": "unknown"
    },
    {
      "criterion": "Patients with a diagnosis of dermatomyositis on steroid-sparing agent and/or systemic steroids (maximum dose of prednisone 1mg/Kg) and still having cutaneous disease activity of at least 5 on the CDASI scale.",
      "label": "met"
    },
    {
      "criterion": "If on immunosuppressive treatments and/or steroids, patients must be on stable doses for at least 4 weeks (28 days).",
      "label": "unknown"
    },
    {
      "criterion": "Patients must undergo age appropriate cancer screening.",
      "label": "met"
    },
    {
      "criterion": "Females of childbearing potential (FCBP) must have a negative pregnancy test at screening (day 0 of the study and every month throughout the study).",
      "label": "unknown"
    },
    {
      "criterion": "While on investigational product and for at least 28 days after taking the last dose of investigational product.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Increasing or changing dose of topical therapy within 14 days of study day 0 (including but not limited to topical corticosteroids, tacrolimus, pimecrolimus).",
      "label": "not_met"
    },
    {
      "criterion": "Increasing or changing systemic steroids dosing within 28 days of study day 0.",
      "label": "met"
    },
    {
      "criterion": "Increasing or changing dosing for concurrent therapy agents within 28 days or 5 half-lives of the biologic agent, whichever is longer, before study day 0: methotrexate, azathioprine, mycophenolate mofetil, hydroxychloroquine, dapsone, leflunomide, cyclosporine, biologic agents (anti-TNFs), IVIG, rituximab.",
      "label": "unknown"
    },
    {
      "criterion": "History of any clinically significant (as determined by the investigators) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major uncontrolled disease.",
      "label": "not_met"
    }
  ],
  "notes": "Patient has a history of systemic mastocytosis with flares, currently on steroid taper and home regimen. She responded well to IV steroids and diphenydramine but failed aspirin challenge due to adverse reaction.",
  "_meta": {
    "topic_id": "10",
    "trial_id": "NCT03529955",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}